In the 18th month following the failure of the biogene company to declare its main drug of Alzheimer’s, it was a 180-degree reversal. On Oct.22, the biogene announced that the company plans to submit the drug to the Food and Drug Administration for review in early 2020 based on a new analysis of the larger data set, and said the company’s R & D drug can relieve the mental decline of some of the patients with Alzheimer’s disease.
Alzheimer’s disease is a progressive neurodegenerative disease with hidden onset. The clinical features of comprehensive dementia, such as memory impairment, aphasia, aphasia, visual spatial skill impairment, executive dysfunction and personality and behavior changes, are unknown so far. Patients with Alzheimer’s disease before the age of 65 are called Alzheimer’s disease and those with Alzheimer’s disease after the age of 65 are called Alzheimer’s disease. The disease was first described by German doctor Alois Alzheimer as a case of a 56-year-old woman reported by, Alois Alztheimer in 1907, showing rapid progressive memory loss. Delusion, after hospitalization, there are directional disorders, speech difficulties, and unable to learn. Although there was a serious cognitive deficit, the neurological signs of the patients were basically normal. Cadaveric anatomy showed brain atrophy, neurofibrillar tangles and pathological changes of neuronal plaques. In the future, people named this kind of disease Alzheimer’s disease.
With the increase of life expectancy, AD has become a common type of dementia, accounting for 50% of all dementia patients. Among the elderly over 65 years old, the annual incidence of AD is about 1%. With the increase of age, the prevalence rate of AD increases about 1% with the increase of age. The disease is often sporadic, more in women than in men, and the course of disease in female patients is often longer than that in male patients. With the aging of the population, the incidence of AD has increased year by year, seriously endangering the physical and mental health and quality of life of the elderly, causing serious pain to patients, bringing heavy burden to the family and society, has become a serious social problem, causing national politics. The government and the medical profession are generally concerned.
People with Alzheimer’s disease have an eraser in their minds, and their loved ones can only watch them, erase their familiar world and life’s past bit by bit, and slowly fall into chaotic memory.
Over the age of 65, the risk of illness is doubled every five years; at the age of 85, almost half of the old people will have cognitive impairment, some of which will shift to Alzheimer’s disease; women are higher than men; at the same time, in the immediate family, if they are present, There is also a certain increase in the risk of illness of their families. At the same time, there has been an increase in the risk of Alzheimer’s disease in patients with minor cognitive impairment, those with head trauma, and post-stroke neuropsychiatric syndrome.
As the most common dementia disease in the middle-aged and the elderly, Alzheimer’s disease can be called chronic “terminal disease”. After the disease, memory and cognitive function will be gradually lost until the ability to think and act is lost, and life can not take care of itself at all. According to statistics, the number of dementia patients worldwide reached 46.8 million in 2015, of which 50%-75% are Alzheimer’s patients. It is speculated that there will be 9.9 million new dementia patients this year and 131 million Alzheimer’s patients by 2050. China already ranks first in the world in Alzheimer’s disease and one of the fastest-growing countries in the world. Who? There is a risk of Alzheimer’s disease, and worse still, there is no special treatment for Alzheimer’s disease. In addition to Alzheimer’s drug research and development over the years, scientists have focused on more convenient and rapid vaccine development.
In 2016, Australian scientists successfully developed the first combined vaccine, which can induce mouse and human brain tissue to produce antibodies against these two proteins, thereby effectively preventing Alzheimer’s disease. The study suggests that Alzheimer’s vaccines can be used in early Alzheimer’s patients and even in healthy people at risk. In early trials, although vaccines significantly reduced the accumulation of these two proteins, in human trials, many vaccines caused brain swelling in subjects. Researchers from Southwest University developed an Alzheimer’s disease vaccine in 2018, which allows the brains of mice to swell.
Anton Porsteinsson, lead researcher and director of nursing, research and education programs for Alzheimer’s disease at the University of Rochester, said: “the first third phase of the study of biological gene Adukanu has shown that the removal of sniper and amyloid β proteins can reduce the clinical decline of Alzheimer’s disease, bringing hope to the medical community, patients and families, and the global Alzheimer’s disease population has been waiting for this moment to come.”